The Kobo Biotech resolution plan approval NCLT 2026 marks a major development under India’s Insolvency and Bankruptcy Code (IBC) framework, as the Hon’ble National Company Law Tribunal (Hyderabad Bench) has approved the resolution plan submitted by Beaufond Industries Limited, a company incorporated under the Companies Act, 2013. This approval was granted vide order dated May 11, 2026, in relation to IA (Plan) No. 01 of 2026 in CP (IB) No. 277/7/HDB/2023.

This development is a significant milestone in the Beaufond Industries takeover Kobo Biotech restructuring process, which has been closely monitored by stakeholders and financial creditors. The approval comes after the Committee of Creditors (CoC) had earlier cleared the resolution plan during its meeting held on March 17, 2026, followed by submission before the NCLT.

The entire process is part of the corporate insolvency resolution process news India, governed under the SEBI Regulation 30 disclosure insolvency update India, ensuring transparency and regulatory compliance in listed entity restructuring.

Background of Corporate Insolvency Process

Kobo Biotech Limited, undergoing insolvency proceedings, was admitted under the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The objective of the process was to revive the company through a structured resolution plan rather than liquidation.

The approved resolution plan was submitted by Beaufond Industries Limited (Successful Resolution Applicant), which is a diversified entity with business interests across multiple sectors including IT, telecom products, metals, machinery, agriculture, textiles, sports equipment, and real estate.

Key Financial Structure of Resolution Plan

Under the approved plan, the total financial outlay is approximately ₹70.11 crore, which includes:

• Payment of CIRP costs: around ₹2.30 crore
• Settlement of Financial Creditors: approximately ₹67.78 crore
• Token payments to operational creditors (employees, statutory dues, others)

This structured payout reflects a comprehensive financial creditors payment plan restructuring scheme, ensuring that major creditors receive resolution while maintaining continuity of business operations.

Additionally, the resolution plan also includes an equity upside mechanism for assenting financial creditors, offering potential shareholding benefits in the post-restructuring entity.

Net Worth and Asset Position

As per audited financials:

• Pre-resolution net worth of Kobo Biotech: ₹132.91 crore (as of March 31, 2024)
• Total assets: ₹71.39 crore

Post-implementation, the financial structure will undergo significant transformation as the assets and business of the resolution applicant are merged with the corporate debtor under a structured IBC resolution plan Hyderabad bench order 2026.

The net worth of Beaufond Industries Limited, as per audited financials (March 31, 2025), stands at approximately ₹333.18 crore, which plays a key role in the revival strategy.

Shareholding Pattern Changes

The approved resolution plan introduces a major restructuring of ownership under the Kobo Biotech corporate insolvency resolution process news framework.

Pre-Resolution Shareholding:

• Promoter Group: 44.95%
• Public Shareholders: 55.05%

Post-Resolution Structure:

• Major issuance to Resolution Applicant promoter category: 57.23%
• Public shareholders retained: approximately 2% (fully diluted basis)
• Financial creditors: ~3% equity participation
• Remaining structured allocations to minority shareholders and other categories

This restructuring represents a significant ownership shift under the Beaufond Industries promoter acquisition plan, aligning control with the incoming resolution applicant.

Business Strategy Post-Resolution

The resolution plan outlines a clear corporate restructuring strategy focused on revival and operational sustainability. The key objectives include:

• Revival of Kobo Biotech as a functional pharmaceutical manufacturing unit
• Professionalisation of management and governance structure
• Regulatory compliance strengthening
• Operational restructuring and efficiency improvement
• Integration with diversified business ecosystem of Beaufond Industries

This forms part of a broader corporate restructuring India insolvency update news, aimed at turning stressed assets into productive business units.

Monitoring Committee and Governance

Post approval, the company will be managed by a Monitoring Committee, which includes:

• Resolution Professional
• Representative of CoC (largest voting share)
• Nominee of Resolution Applicant

This committee will oversee implementation until full transfer and merger completion, ensuring compliance with the approved resolution framework.

The existing Board of Directors will remain suspended until completion of the process.

Legal and Regulatory Framework

The disclosure is made under:

• Regulation 30 of SEBI (LODR) Regulations, 2015
• Schedule III compliance requirements
• SEBI Master Circular (updated 2024 amendments)
• BSE Guidance Notes for corporate disclosures

This ensures that the entire resolution process is transparent and accessible to investors tracking stock exchange insolvency resolution update India developments.

Impact on Investors and Market Outlook

While immediate financial ratios such as P/E and RONW are not yet available, they will be recalculated post-implementation. The restructuring is expected to significantly alter:

• Capital structure
• Earnings potential
• Asset base
• Business operations

For investors tracking pharma company revival strategy India insolvency and bankruptcy code update, this development represents a potential long-term turnaround opportunity.

Conclusion

The approval of the Kobo Biotech resolution plan by NCLT Hyderabad Bench 2026 underlines a major step in India’s insolvency resolution ecosystem. With Beaufond Industries Limited taking the lead as the resolution applicant, the company is set for a structured revival backed by capital infusion, debt restructuring, and operational transformation.

This case highlights how the corporate debt resolution news financial creditors payment plan restructuring scheme under the IBC framework continues to provide a structured pathway for revival of stressed companies while balancing creditor and investor interests.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.